Analyst consensus rating
Kalaris Therapeutics Analyst Rating: none
KLRS is rated none by 7 analysts with a $18.71 target. As of 2026-09-03.
Direct answer
Kalaris Therapeutics's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.71.
Forecast evidence checked September 3, 2026.
Get free Kalaris Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.90
- Average price target
- $18.71
- High price target
- $25.00
- Low price target
- $7.00
- Low target gap
- +79.5%
- Target upside
- +379.9%
- High target gap
- +541%
- Target range width
- 461.5%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- September 3, 2026
- Valid through
- September 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kalaris Therapeutics?
Kalaris Therapeutics has a verified none consensus. The same dataset has an average price target of $18.71.
How far are Kalaris Therapeutics's low and high targets from the recorded price?
The low target implies +79.5%, while the high target implies +541%.
How many analysts are included in Kalaris Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Kalaris Therapeutics's target upside or downside calculated?
The average target of $18.71 is divided by the recorded price of $3.90, then one is subtracted to produce +379.9%. This does not guarantee a future return.
When was Kalaris Therapeutics's analyst forecast verified?
The data was verified on 2026-09-03. The dataset is valid through 2026-09-10.